United States Prevalence of Atopic Dermatitis in Adults and Pediatrics by Race and Ethnicity

Andrew Alexis¹, Dave Nelson², Candrice Heath³, Russel Burge⁴, Beth Mitchell⁵, Andrea Cohee⁶, Evangeline Pierce⁷, Amber Rock Atwater⁸, Raj Chovatiya⁹

¹Weill Cornell Medicine, New York, NY, USA; ²Eli Lilly and Company, Indianapolis, IN, USA; ³Lewes Katz School of Medicine at Temple University, Philadelphia, PA, USA; ⁴Chicago Medical School, Rosalind Franklin University of Medicine and Science, Chicago, IL, USA; ⁵Center for Medical Dermatology and Immunology, Chicago, IL, USA

BACKGROUND

- To address health disparities in diverse racial and ethnic populations, current and robust data on atopic dermatitis (AD) prevalence by race/ethnicity are needed.
- Although data on pediatric prevalence of AD in diverse race/ethnicity populations have been reported, there are limited epidemiologic data in adult populations with AD.

OBJECTIVES

- To estimate United States (US) prevalence rates for AD by diverse populations, including race/ethnicity groups, age groups, and sex.
- To evaluate the likelihood of the presence of AD, adjusting for multiple factors associated with estimated prevalence rates of AD.

RESULTS

In ALL age groups combined, AD prevalence was higher in females versus males across all race groups.

In children, AD prevalence was similar in males and females.

There was a higher prevalence of AD in 18-64 year-old respondents relative to respondents 265 years driven by the prevalence in females.

CONCLUSIONS

- Total US prevalence of patient-reported AD in adults is approximately 18 million.
- AD prevalence rates were higher in children and higher in adult females.
- Hispanic adults have a lower prevalence of AD than all other adult groups.
- Additional studies are needed to understand sociodemographic variations in AD prevalence.

United States Prevalence of Atopic Dermatitis: Pediatric and Adult populations

Method: American LifeTime Surveys (ALS 2017)
- Next generation of national probability sample surveys that measure the health status of individuals across their lifetime.
- 25,000 (12,500 adults, 12,500 children, 18 months to 17 years old) interviewed in person

DISCLOSURES

- No conflicts of interest.
- Funding: Eli Lilly and Company, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L’Oréal, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CorEvitas

Acknowledgments

- Andrew Alexis is supported by National Institutes of Health grants R01AR069069 and R01AR069069 (in part) and the American Academy of Dermatology

Copyright © 2024 Eli Lilly and Company

Sponsored by Eli Lilly and Company

Revolutionizing Atopic Dermatitis (RAD) Conference; Chicago, IL, USA; 8-10 June 2024